• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Zimmer Biomet Holdings Inc.

    6/20/25 4:32:27 PM ET
    $ZBH
    Industrial Specialties
    Health Care
    Get the next $ZBH alert in real time by email
    S-8 1 d187611ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on June 20, 2025

    Registration No. 333-    

     

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    ZIMMER BIOMET HOLDINGS, INC.

    (Exact Name of Registrant as Specified in Its Charter)

     

     

     

    Delaware   13-4151777

    (State or Other Jurisdiction of

    Incorporation or Organization)

     

    (I.R.S. Employer

    Identification No.)

    345 East Main Street

    Warsaw, Indiana 46580

    (Address of Principal Executive Offices)

     

     

    ZIMMER BIOMET HOLDINGS, INC. 2009 STOCK INCENTIVE PLAN

    (Full Title of the Plan)

     

     

    Chad F. Phipps

    Senior Vice President, General Counsel and Secretary

    Zimmer Biomet Holdings, Inc.

    345 East Main Street

    Warsaw, Indiana 46580

    (Name and address of agent for service)

    (574) 373-3333

    (Telephone number, including area code, of agent for service)

    Copy to:

    Juliano Banuelos, Esq.

    Orrick, Herrington & Sutcliffe LLP

    405 Howard Street

    San Francisco, California 94105-2669

    (415) 773-5700

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☒    Accelerated filer   ☐
    Non-accelerated filer   ☐    Smaller reporting company   ☐
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     
     


    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    Item 1. Plan Information.

    Information required by this Item 1 to be contained in the Section 10(a) prospectus is omitted from this registration statement on Form S-8 (the “Registration Statement”) in accordance with Rule 428 under the Securities Act of 1933, as amended (the “Securities Act”) and the instructions to Form S-8. In accordance with the rules and regulations of the Securities and Exchange Commission (the “Commission”) and the instructions to Form S-8, such documents are not being filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 under the Securities Act.

    Item 2. Registrant Information and Employee Plan Annual Information.

    Information required by this Item 2 to be contained in the Section 10(a) prospectus is omitted from this Registration Statement in accordance with Rule 428 under the Securities Act and the instructions to Form S-8. In accordance with the rules and regulations of the Commission and the instructions to Form S-8, such documents are not being filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 under the Securities Act.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference

    The following documents filed by Zimmer Biomet Holdings, Inc. (the “Registrant”) with the Commission pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange Act”), are incorporated herein by reference:

     

      (a)

    The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (File No. 001-16407) filed with the Commission on February 25, 2025;

     

      (b)

    The information specifically incorporated by reference into the Registrant’s Annual Report on Form 10-K for the fiscal year ended December  31, 2024 from its Definitive Proxy Statement on Schedule 14A (File No. 001-16407) filed with the Commission on April 14, 2025;

     

      (c)

    The Registrant’s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2025 (File No. 001-16407) filed with the Commission on May 5, 2025;

     

      (d)

    All other reports filed pursuant to Section 13(a) or 15(d) of the Exchange Act since the end of the fiscal year covered by the Registrant’s Annual Report referred to in (a) above; and

     

      (e)

    The description of the Registrant’s common stock contained in the Registrant’s Registration Statement on Form 10-12B, filed on March 26, 2001, including any amendment or report filed for the purpose of updating such description.

    All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment, which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part hereof from the date of the filing of such documents, except as to specific sections of such statements as set forth therein.


    Unless expressly incorporated into this Registration Statement, a report furnished on Form 8-K prior or subsequent to the date hereof shall not be incorporated by reference into this Registration Statement, except as to specific sections of such statements as set forth therein. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in any subsequently filed document, which also is deemed to be incorporated by reference herein, modifies or supersedes such statement.

    Item 4. Description of Securities

    Not applicable.

    Item 5. Interests of Named Experts and Counsel

    Not applicable.

    Item 6. Indemnification of Directors and Officers

    Section 145 of the Delaware General Corporation Law (the “DGCL”) provides that a corporation may indemnify any current or former director, officer, employee or agent against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with civil, criminal, administrative or investigative actions, suits or proceedings, other than a derivative action by or in the right of the corporation, if the director, officer, employee or agent acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, if he or she had no reasonable cause to believe his or her conduct was unlawful. A similar standard is applicable in the case of derivative actions, except that indemnification only extends to expenses incurred in connection with the defense or settlement of such actions, and the statute requires court approval before there can be any indemnification where the person seeking indemnification has been found liable to the corporation. The statute provides that it is not exclusive of other indemnification that may be granted by any by-law, agreement, vote of stockholders or disinterested directors or otherwise.

    The Registrant’s Restated Certificate of Incorporation provides that each person who was or is made a party or is threatened to be made a party to or is involved in any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that such person, or a person of whom such person is the legal representative, is or was a director or officer of the Registrant or, while a director or officer of the Registrant, is or was serving at the request of the Registrant as a director, officer, employee or agent of another corporation or of a partnership, joint venture, trust or other enterprise, including service with respect to employee benefit plans, will be indemnified and held harmless by the Registrant to the fullest extent authorized by the DGCL, as the same exists or may hereafter be amended to provide broader indemnification rights than authorized prior to such amendment. The Registrant will indemnify such persons against the expenses, liabilities and loss, including attorneys’ fees, judgments, fines and amounts paid in settlement, reasonably incurred by the person in connection with the action, suit or proceeding if the following standards are met:

     

      •  

    the person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the Registrant’s best interests, and

     

      •  

    with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful.

    Section 145 of the DGCL also permits a corporation to pay expenses of defense incurred by a director or officer in defending any civil, criminal, administrative or investigative action, suit or proceeding in advance of the final disposition of such action, suit or proceeding upon receipt (in the case of a current director or officer) of an undertaking to repay all amounts advanced if it is ultimately determined that such director or officer is not entitled to be indemnified by the corporation. The Restated Certificate of Incorporation contains such a provision.


    Such rights are not exclusive of any other right which any person may have or thereafter acquire under any statute, any provision of the Restated Certificate of Incorporation or the Registrant’s Restated Bylaws, or any agreement, vote of stockholders or disinterested directors or otherwise. The Registrant’s Restated Certificate of Incorporation also specifically authorizes the Registrant to maintain insurance and to grant similar indemnification rights to its employees or agents.

    The Registrant has provided, consistent with the DGCL, in its Restated Certificate of Incorporation that a director of the Registrant shall not be personally liable to the Registrant or its stockholders for monetary damages for breach of fiduciary duty as a director, except for liability for:

     

      •  

    any breach of the director’s duty of loyalty to the Registrant or its stockholders;

     

      •  

    acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law;

     

      •  

    any transactions from which the director derived an improper personal benefit; or

     

      •  

    any matter in respect of which the director would be liable under Section 174 of the DGCL.

    Neither the amendment nor repeal of such provision will eliminate or reduce the effect of such provision in respect of any matter occurring, or any cause of action, suit or claim that, but for such provision, would accrue or arise prior to such amendment or repeal.

    The Registrant has entered into indemnification agreements with its directors and executive officers providing for mandatory indemnification and advancement of expenses to the fullest extent permitted by applicable law.

    In addition, the Registrant has a directors’ and officers’ liability policy that insures against certain liabilities, including liabilities under the Securities Act, subject to applicable retentions.

    Item 7. Exemption From Registration Claimed

    Not applicable.

    Item 8. Exhibits

     

    Exhibit Number

     

    Description

      5.1*   Opinion of Orrick, Herrington & Sutcliffe LLP.
     23.1*   Consent of PricewaterhouseCoopers LLP, independent registered public accounting firm.
     23.2*   Consent of Orrick, Herrington & Sutcliffe LLP (filed as part of Exhibit 5.1 to this Registration Statement).
     24.1*   Powers of Attorney (filed as part of signature page of this Registration Statement).
     99.1   Zimmer Biomet Holdings, Inc. 2009 Stock Incentive Plan, as amended and restated (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed June 3, 2025).
    107*   Filing Fee Table.

     

    *

    Filed herewith.


    Item 9. Undertakings

     

    a.

    The undersigned Registrant hereby undertakes:

     

      (1)

    To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

     

      (i)

    To include any prospectus required by Section 10(a)(3) of the Securities Act;

     

      (ii)

    To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement; and

     

      (iii)

    To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;

    Provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) above do not apply if the information required to be included in a post-effective amendment by such paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.

     

      (2)

    That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

      (3)

    To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    b.

    The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    c.

    Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered hereby, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Warsaw, State of Indiana on the 20th day of June 2025.

     

    ZIMMER BIOMET HOLDINGS, INC.

    (Registrant)

    By   /s/ Ivan Tornos
     

    Ivan Tornos

    President and Chief Executive Officer

    (Principal Executive Officer)

    POWER OF ATTORNEY

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in their respective capacities and on the respective dates indicated opposite their names. Each person whose signature appears below hereby authorizes each of Ivan Tornos, Suketu Upadhyay and Chad Phipps, each with full power of substitution, to execute in the name and on behalf of such person any amendment (including any post-effective amendment) to this Registration Statement and to file the same, with exhibits thereto, and other documents in connection therewith, making such changes in this Registration Statement as the Registrant deems appropriate, and appoints each of Ivan Tornos, Suketu Upadhyay and Chad Phipps, each with full power of substitution, attorney-in-fact to sign any amendment (including any post-effective amendment) to this Registration Statement and to file the same, with exhibits thereto, and other documents in connection therewith.

     

    Signature

      

    Title

     

    Date

    /s/ Ivan Tornos

    Ivan Tornos

      

    President, Chief Executive Officer and Director

    (Principal Executive Officer)

      June 20, 2025

    /s/ Suketu Upadhyay

    Suketu Upadhyay

      

    Chief Financial Officer and Executive Vice President – Finance, Operations and Supply Chain

    (Principal Financial Officer)

      June 20, 2025

    /s/ Paul Stellato

    Paul Stellato

      

    Vice President, Controller and Chief Accounting Officer

    (Principal Accounting Officer)

      June 20, 2025

    /s/ Betsy Bernard

    Betsy Bernard

       Director   June 20, 2025


    Signature

      

    Title

     

    Date

    /s/ Michael Farrell

    Michael Farrell

       Director   June 20, 2025

    /s/ Robert Hagemann

    Robert Hagemann

       Director   June 20, 2025

    /s/ Arthur Higgins

    Arthur Higgins

       Director   June 20, 2025

    /s/ Maria Teresa Hilado

    Maria Teresa Hilado

       Director   June 20, 2025

    /s/ Syed Jafry

    Syed Jafry

       Director   June 20, 2025

    /s/ Sreelakshmi Kolli

    Sreelakshmi Kolli

       Director   June 20, 2025

    /s/ Devdatt Kurdikar

    Devdatt Kurdikar

       Director   June 20, 2025

    /s/ Louis A. Shapiro

    Louis A. Shapiro

       Director   June 20, 2025
    Get the next $ZBH alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ZBH

    DatePrice TargetRatingAnalyst
    7/15/2025$135.00Neutral → Buy
    Roth Capital
    12/17/2024$125.00 → $128.00Neutral → Overweight
    Analyst
    9/10/2024Peer Perform
    Wolfe Research
    7/1/2024$140.00 → $115.00Overweight → Neutral
    Piper Sandler
    5/30/2024$129.00Neutral
    Goldman
    5/21/2024$150.00Hold → Buy
    Argus
    1/4/2024$135.00 → $125.00Outperform → In-line
    Evercore ISI
    10/20/2023$120.00Neutral
    ROTH MKM
    More analyst ratings

    $ZBH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Zimmer Biomet upgraded by Roth Capital with a new price target

      Roth Capital upgraded Zimmer Biomet from Neutral to Buy and set a new price target of $135.00

      7/15/25 8:30:57 AM ET
      $ZBH
      Industrial Specialties
      Health Care
    • Zimmer Biomet upgraded by Analyst with a new price target

      Analyst upgraded Zimmer Biomet from Neutral to Overweight and set a new price target of $128.00 from $125.00 previously

      12/17/24 8:26:36 AM ET
      $ZBH
      Industrial Specialties
      Health Care
    • Wolfe Research initiated coverage on Zimmer Biomet

      Wolfe Research initiated coverage of Zimmer Biomet with a rating of Peer Perform

      9/10/24 8:03:41 AM ET
      $ZBH
      Industrial Specialties
      Health Care

    $ZBH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Thornal Kevin R

      3 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)

      7/7/25 4:15:32 PM ET
      $ZBH
      Industrial Specialties
      Health Care
    • Group Pres, EMEA Van Zuilen Wilfred converted options into 2,631 shares and covered exercise/tax liability with 692 shares, increasing direct ownership by 10% to 21,473 units (SEC Form 4)

      4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)

      7/3/25 4:10:43 PM ET
      $ZBH
      Industrial Specialties
      Health Care
    • SEC Form 4 filed by Director Higgins Arthur J

      4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)

      7/2/25 4:56:05 PM ET
      $ZBH
      Industrial Specialties
      Health Care

    $ZBH
    Leadership Updates

    Live Leadership Updates

    See more
    • Zimmer Biomet Appoints Kevin Thornal as Group President, Global Businesses and the Americas

      WARSAW, Ind., May 27, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the appointment of Kevin Thornal as Group President, Global Businesses and the Americas. Reporting to Chairman-Elect, President and CEO Ivan Tornos, Mr. Thornal will join the Company on July 1, 2025 to oversee the Americas commercial organization and lead business strategy and execution for its global Knees, Hips, S.E.T. and Data, Technology, and Enabling Solutions units. "Kevin is an incredible addition to our leadership team at an e

      5/27/25 7:30:00 AM ET
      $ZBH
      Industrial Specialties
      Health Care
    • Zimmer Biomet Names Kristen Cardillo as Senior Vice President, Chief Communications Officer

      WARSAW, Ind., March 6, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the appointment of Kristen Cardillo as Senior Vice President, Chief Communications Officer. Reporting to President and CEO Ivan Tornos, Ms. Cardillo will join the Company on March 10, 2025, to lead Zimmer Biomet's global communications strategy, enhancing engagement with key stakeholders and amplifying the Company's position as a leader in MedTech. "Kristen's expertise in shaping compelling corporate narratives and leading high-impac

      3/6/25 7:30:00 AM ET
      $ZBH
      Industrial Specialties
      Health Care
    • Zimmer Biomet Appoints Jehanzeb Noor as Senior Vice President, Chief Strategy, Innovation and Business Development Officer

      WARSAW, Ind., Feb. 27, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that Jehanzeb Noor is joining the Company as Senior Vice President, Chief Strategy, Innovation and Business Development Officer. He will report to Ivan Tornos, President and CEO of Zimmer Biomet. In his new role, Mr. Noor will be responsible for leading strategy development and execution and all facets of M&A, including the integration for our pending acquisition of Paragon 28. In addition, he will have oversight of the research and

      2/27/25 7:30:00 AM ET
      $ZBH
      Industrial Specialties
      Health Care

    $ZBH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Zimmer Biomet Announces Definitive Agreement to Acquire Monogram Technologies, Expanding Robotics Suite with Autonomous Solutions

      Proposed transaction creates the broadest, most flexible portfolio of orthopedic robotics and navigation technologies to meet surgeons' needs  Acquisition expected to be neutral to adjusted earnings per share in 2025 – 2027 and accretive thereafter and to contribute to revenue growth beginning in 2027 WARSAW, Ind. and AUSTIN, Texas, July 14, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, and Monogram Technologies Inc. (NASDAQ:MGRM), an orthopedic robotics company, today announced they have entered into a definitive agreement for Zimmer Biomet to acquire all outstanding shares of stock of Monogram for an upfront payment of $4.04 per

      7/14/25 7:30:00 AM ET
      $MGRM
      $ZBH
      Medical/Dental Instruments
      Health Care
      Industrial Specialties
    • Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2025 Financial Results

      WARSAW, Ind., July 9, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its second quarter earnings conference call will be webcast on Thursday, August 7, 2025 at 8:30 a.m. ET. A news release detailing the quarterly results will be made available that day at 6:30 a.m. ET. The live audio webcast can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. It will be available for replay following the conference call. Individuals in the U.S. and Canada who wish to dial into the conference call may do so

      7/9/25 7:30:00 AM ET
      $ZBH
      Industrial Specialties
      Health Care
    • Treace Files Patent Infringement Suit Against Zimmer Biomet to Protect Lapiplasty® Bunion Technology

      PONTE VEDRA, Fla., June 05, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® procedures, today announced that it filed a lawsuit against Zimmer Biomet Holdings, Inc. and Paragon 28, Inc. (collectively, "Zimmer") (NYSE:ZBH), alleging infringement of 4 patents related to Treace's innovative Lapiplasty® 3D Bunion Correction® technologies. The suit was filed in the United States District Court for the District of Delaware, and seeks injunctive relief and damages. "Treac

      6/5/25 1:00:00 PM ET
      $TMCI
      $ZBH
      Medical/Dental Instruments
      Health Care
      Industrial Specialties

    $ZBH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Jafry Syed A. bought $223,641 worth of shares (2,135 units at $104.75), increasing direct ownership by 111% to 4,060 units (SEC Form 4)

      4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)

      11/13/23 4:02:02 PM ET
      $ZBH
      Industrial Specialties
      Health Care
    • Begley Christopher B bought $117,114 worth of shares (1,000 units at $117.11), increasing direct ownership by 39% to 3,540 units (SEC Form 4)

      4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)

      9/29/23 4:05:41 PM ET
      $ZBH
      Industrial Specialties
      Health Care

    $ZBH
    SEC Filings

    See more
    • Zimmer Biomet Holdings Inc. filed SEC Form 8-K: Other Events, Regulation FD Disclosure

      8-K - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Filer)

      7/14/25 7:40:25 AM ET
      $ZBH
      Industrial Specialties
      Health Care
    • Zimmer Biomet Holdings Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Entry into a Material Definitive Agreement

      8-K - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Filer)

      6/30/25 4:15:36 PM ET
      $ZBH
      Industrial Specialties
      Health Care
    • SEC Form S-8 filed by Zimmer Biomet Holdings Inc.

      S-8 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Filer)

      6/20/25 4:32:27 PM ET
      $ZBH
      Industrial Specialties
      Health Care

    $ZBH
    Financials

    Live finance-specific insights

    See more
    • Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2025 Financial Results

      WARSAW, Ind., July 9, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its second quarter earnings conference call will be webcast on Thursday, August 7, 2025 at 8:30 a.m. ET. A news release detailing the quarterly results will be made available that day at 6:30 a.m. ET. The live audio webcast can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. It will be available for replay following the conference call. Individuals in the U.S. and Canada who wish to dial into the conference call may do so

      7/9/25 7:30:00 AM ET
      $ZBH
      Industrial Specialties
      Health Care
    • Zimmer Biomet Announces Quarterly Dividend for Second Quarter of 2025

      WARSAW, Ind., May 30, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the second quarter of 2025. The cash dividend of $0.24 per share is payable on or about July 31, 2025 to stockholders of record as of the close of business on June 26, 2025. About Zimmer Biomet Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamle

      5/30/25 7:00:00 AM ET
      $ZBH
      Industrial Specialties
      Health Care
    • Zimmer Biomet Announces First Quarter 2025 Financial Results

      First quarter net sales of $1.909 billion increased 1.1% and 2.3% on a constant currency1 basisFirst quarter diluted earnings per share were $0.91; adjusted1 diluted earnings per share were $1.81Company updates full-year 2025 reported revenue guidance to include the Paragon 28 acquisition and currency expectations, and full-year 2025 adjusted1 earnings per share guidance to include Paragon 28, currency and the impact from current tariff proposalsWARSAW, Ind., May 5, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended March 31, 2025.  The Company reported first quarter net sales of $1.909 billion, an increase of 1.1% ove

      5/5/25 6:30:00 AM ET
      $ZBH
      Industrial Specialties
      Health Care

    $ZBH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Zimmer Biomet Holdings Inc.

      SC 13G - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)

      11/14/24 1:22:34 PM ET
      $ZBH
      Industrial Specialties
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Zimmer Biomet Holdings Inc.

      SC 13G/A - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)

      11/13/24 1:44:56 PM ET
      $ZBH
      Industrial Specialties
      Health Care
    • SEC Form SC 13G filed by Zimmer Biomet Holdings Inc.

      SC 13G - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)

      2/14/24 10:02:59 AM ET
      $ZBH
      Industrial Specialties
      Health Care